Baudax Bio, Inc.
BXRXQ
$0.00
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -77.21% | -60.94% | -34.97% | 17.59% | 79.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -77.21% | -60.94% | -34.97% | 17.59% | 79.89% |
| Cost of Revenue | 731.94% | 361.66% | 195.07% | 95.99% | -76.11% |
| Gross Profit | -2,446.59% | -1,155.46% | -504.04% | -228.35% | 89.37% |
| SG&A Expenses | -59.89% | -72.05% | -75.81% | -67.17% | -44.81% |
| Depreciation & Amortization | -89.91% | -94.95% | -96.64% | -97.48% | -75.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.23% | -45.92% | -56.86% | -57.04% | -48.55% |
| Operating Income | 21.21% | 45.76% | 56.71% | 56.74% | 48.57% |
| Income Before Tax | -301.66% | -41,726.87% | -126.84% | -30.89% | 119.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -301.66% | -41,726.87% | -126.84% | -30.89% | 119.33% |
| Earnings from Discontinued Operations | 156.72% | 17.91% | -106.20% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.43% | -337.57% | -120.76% | -197.42% | 69.64% |
| EBIT | 21.21% | 45.76% | 56.71% | 56.74% | 48.57% |
| EBITDA | 21.60% | 45.73% | 56.69% | 56.69% | 48.44% |
| EPS Basic | -104.22% | -398.31% | 29.11% | 39.20% | 112.26% |
| Normalized Basic EPS | 95.19% | 94.50% | 93.11% | 87.20% | 84.69% |
| EPS Diluted | -105.44% | -719.98% | 42.67% | 45.10% | 109.49% |
| Normalized Diluted EPS | 94.85% | 94.27% | 92.90% | 86.91% | 85.70% |
| Average Basic Shares Outstanding | 2,403.89% | 1,955.74% | 1,187.79% | 505.98% | 256.41% |
| Average Diluted Shares Outstanding | 2,377.44% | 1,921.49% | 1,156.29% | 487.47% | 260.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |